Delivering tomorrow's treatments for today's patients

Leigh Syndrome International Consortium Grant Cycle 2021

The Leigh Syndrome International Consortium’s grant cycle is open for submissions from 25 October 2021 until 22 November 2021. Funding of up to USD150,000 is available for research with a Leigh syndrome focus; recipients will be announced in December with the expectation that funding will commence from January 2022.

Please see below the eligibility criteria and submission requirements.

Scope of Projects

All submissions must have a Leigh syndrome focus. The following research categories and priorities have been established:

Translational Research

  • Projects which contribute new tools for advancing basic research from the benchtop to the clinic, especially novel cellular and animal models or their application to deepen insights, biomarkers, diagnostics, or therapeutics for mitochondrial disease

Clinical Research

  • Patient-centered projects which explore means of achieving improved diagnoses, the understanding of the natural history of specific mitochondrial diseases or the development of therapeutic approaches for treating mitochondrial disease
  • Retrospective analyses on existing data sets or well-designed prospective analyses that will help inform the understanding of Leigh syndrome natural history are welcomed
  • Projects that utilize existing outcome measures to assess disease progression as well as the development of new clinically relevant outcome measures that can serve as endpoints for future clinical trials are encouraged
  • Interventional clinical trials are NOT within scope of this RFP

Eligibility and Funding Mechanisms

Applicants must be established, independent investigators. Postdoctoral Fellows are NOT eligible for awards under this RFP.

  • The consortium intends to fund up to 150,000 USD in projects in the current grant cycle
  • Budgets should not exceed 50,000 USD over 12 months
    •   Small budget, shorter duration submissions are highly encouraged
  • Applicants may be based anywhere in the world

Note: Budgets may not include indirect (facilities & administration) costs


Application Process

UMDF is stewarding the grant cycle on behalf of the consortium. The application process will proceed as follows:

Proposals may be started on 25 October 2021 and submissions must be processed by 22 November 2021. Applicants are reminded to leave sufficient time for any necessary institutional approvals so as to meet the above timeline. Late submissions will not be considered.

Review Process

The consortium considers rigorous peer review as the foundation of good scientific investment. Applicants may be assured that all submitted information is handled as confidential with any potential reviewer conflicts of interest taken very seriously.


  • All submitted proposals must include a 250 word (maximum) scientific abstract that provides sufficient detail to allow for further review consideration by the consortium
  • Submissions will be reviewed by the Scientific Steering Committee of the Leigh Syndrome International Consortium
  • Scoring/Review criteria include (but are not limited to): Responsiveness to this RFP, relevance to Leigh syndrome, scientific novelty, scientific premise and rigour, and potential to impact the lives of those affected with Leigh syndrome
  • All applicants will receive notification if their submission will be scored and a summary of the result


Questions? Please email